Premium
EMACO in High Risk Gestational Trophoblast Disease ‐ The Australian Experience
Author(s) -
Quinn M.,
Murray J.,
Friedlander M.,
Steigrad S.,
Khoo S.,
Marsden D.,
Hammond I.,
Jobling T.
Publication year - 1994
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/j.1479-828x.1994.tb01047.x
Subject(s) - regimen , trophoblast , medicine , disease , gestational trophoblastic disease , cure rate , pregnancy , obstetrics , gestation , fetus , placenta , biology , genetics
Summary: Sixty‐five patients with high‐risk trophoblast disease have been treated with the EMACO combination split regimen therapy in the 10 year period, 1981 to 1990. Four patients died but the remaining 61 (94%) remain free of disease up to 10 years later. Toxicity was manageable in most cases with minimal delay in treatment from myelosuppression. EMACO is a well tolerated regimen with a high cure rate in patients with high‐risk gestational trophoblast disease (GTD).